Circulating let-7f-5p improve risk prediction of prostate cancer in patients with benign prostatic hyperplasia

Abstract

Background: Although the prostate-specific antigen (PSA) testing was widely used for early detection of prostate cancer (PCa), it is difficult for PSA to distinguish the PCa from benign prostatic hyperplasia (BPH) patients. Emerging evidence has shown that microRNA (miRNA) was a promising biomarker for PCa screening. Methods: We applied miRNA profiling from microarray or high-throughput sequencing in Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases to identify the differentially expressed miRNAs in PCa patients (n = 1,017) and controls (n = 413). Then, qRT-PCR analysis was used to validate the expression of candidate miRNAs in our independent cohort, include 66 PCa cases and 63 BPH patients diagnosed by biopsy. The area under the receiver operating characteristic curve (AUC) was conducted to evaluate the diagnostic efficacy of miRNAs and PSA. Results: In the microarray analysis, we identified two consistently differently expressed miRNAs (miR-103a-3p and let-7f-5p) between PCa patients and controls. In the subsequent qRT-PCR analysis, the let-7f-5p was upregulated in PCa compared with BPH patients (P=2.17E-07), but no statistically difference of miR-103a-3p expression was observed (P=0.456). The AUC was 0.904 for combination of lef-7f-5p and PSA, which was significantly higher than that of let-7f-5p (0.782) or PSA (0.795) alone (P=7.55E-04 and P=2.09E-03, respectively). Besides, the results of decision curve analysis and nomogram prediction indicated that combination of let-7f-5p and PSA had superior predictive accuracy of PCa. Conclusions: Our study suggests that plasma let-7f-5p combining PSA could serve as potentially diagnostic biomarkers for PCa.

Integrated miRNA and mRNA Expression Profiles Reveal Differentially Expressed miR-222a as an Antiviral Factor Against Duck Hepatitis A Virus Type 1 Infection

“…let-7f-5p is indispensable for various physiological and biological processes, including cell differentiation ( Wu et al., 2007 ), immune response ( Sathe et al., 2014 ), and angiogenesis ( Nicoloso and Calin, 2008 ). A previous study implicates elevated let-7f-5p expression as a biomarker for multiple malignant diseases, including non-muscle-invasive bladder ( Shee et al., 2020 ) and prostate cancers ( Ge et al., 2020 ). miR-222a, a miR-221/222 cluster component ( Chun-Zhi et al., 2010 ), is aberrantly expressed in hepatocellular carcinoma ( Wang et al., 2019 ), epithelial tumors ( Gaetani et al., 2020 ), and virus-infected cells ( Zhao et al., 2019 ; Song et al., 2020 ).…”

Diagnostic performance of microRNA-34a, let-7f and microRNA-31 in epithelial ovarian cancer prediction

“…Similarly, the diagnostic potential of microRNA-34a and microRNA-31 is analogous to combined microRNA panels for the early diagnosis of EOC. Recent study showed combined diagnostic value of miR-34a and CA-125 could discriminate EOC from normal with an AUC of 0.818, while lower expression of let-7f has the diagnostic value of AUC 0.78 [ 24 29 30 31 32 ]. Moreover, the comparative expression analysis of let-7f in different cancers (colorectal, lung, prostate, papillary thyroid cancer) showed a higher diagnostic value for discriminating respective cancer from the normal [ 29 31 32 33 34 35 ].…”

“…Recent study showed combined diagnostic value of miR-34a and CA-125 could discriminate EOC from normal with an AUC of 0.818, while lower expression of let-7f has the diagnostic value of AUC 0.78 [ 24 29 30 31 32 ]. Moreover, the comparative expression analysis of let-7f in different cancers (colorectal, lung, prostate, papillary thyroid cancer) showed a higher diagnostic value for discriminating respective cancer from the normal [ 29 31 32 33 34 35 ]. Very few reports are available on exploring the diagnostic value of these selected microRNA in EOC; therefore, the discriminative potential of each microRNA and integrated microRNA panel from the present study could aid in predicting early-stage ovarian cancer.…”

Actin-Binding Proteins as Potential Biomarkers for Chronic Inflammation-Induced Cancer Diagnosis and Therapy

“…In recent years, immunotherapy, especially adoptive immunotherapy, has shown great benefits for patients with advanced prostate cancer. Recent research showed that plasma let-7f-5p combined with a prostate-specific antigen is used as a biomarker for the diagnosis of prostate cancer [ 109 , 110 ]. The F-actin-binding protein switch-associated protein 70 (SWAP70, SWAP switch B cell complex 70 kDa subunit) is involved in the activation of B cell transformation.…”